Drug
Advm 022
Advm 022: highest development phase Phase 2, developed by Adverum Biotechnologies. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Adverum Biotechnologies
Trials
| Drug | Phase | Indication |
|---|---|---|
| ADVM-022 NCT05536973 | Phase 2 | Neovascular Age-related Macular Degeneration |
| ADVM-022 NCT03748784 | Phase 1 | Wet Age-related Macular Degeneration |
Latest
No recent events.
Follow Advm 022 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.